Drug Information

Drug General Information
Drug ID
D0L3KA
Former ID
DNCL002379
Drug Name
BP-100-1-01
Indication Acute lymphoblastic leukemia; Acute myeloid leukemia; Chronic myelogenous leukemia; Hematological malignancies; Myelodysplastic syndrome [ICD9: 204.0, 205.0, 205.1, 238.7, 200-209; ICD10:C91.0, C92.0, C92.1, D46, C81-C86] Phase 2 [549112]
Company
Bio-Path Ogden, Utah
Target and Pathway
Target(s) mRNA of GRB2 Target Info Modulator [523107], [533092]
NetPath Pathway EGFR1 Signaling Pathway
Pathway Interaction Database Fc-epsilon receptor I signaling in mast cells
BCR signaling pathway
ErbB4 signaling events
Insulin Pathway
GMCSF-mediated signaling events
IL4-mediated signaling events
TCR signaling in na&#xef
Plasma membrane estrogen receptor signaling
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
Signaling events mediated by PTP1B
EPHB forward signaling
Signaling events regulated by Ret tyrosine kinase
TCR signaling in na&#xef
Signaling events mediated by TCPTP
Angiopoietin receptor Tie2-mediated signaling
SHP2 signaling
IL2-mediated signaling events
IGF1 pathway
EGF receptor (ErbB1) signaling pathway
IL5-mediated signaling events
EGFR-dependent Endothelin signaling events
IL2 signaling events mediated by PI3K
ErbB1 downstream signaling
ErbB2/ErbB3 signaling events
IL3-mediated signaling events
IL6-mediated signaling events
PDGFR-beta signaling pathway
Neurotrophic factor-mediated Trk receptor signaling
Nephrin/Neph1 signaling in the kidney podocyte
PDGFR-alpha signaling pathway
Internalization of ErbB1
Signaling events mediated by Stem cell factor receptor (c-Kit)
EPO signaling pathway
IL2 signaling events mediated by STAT5
Signaling events mediated by VEGFR1 and VEGFR2
a6b1 and a6b4 Integrin signaling
Regulation of Ras family activation
Trk receptor signaling mediated by PI3K and PLC-gamma
EPHA2 forward signaling
VEGFR3 signaling in lymphatic endothelium
FGF signaling pathway
Signaling events mediated by focal adhesion kinase
TGF-beta receptor signaling
References
Ref 549112Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032443)
Ref 523107ClinicalTrials.gov (NCT01159028) Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS. U.S. National Institutes of Health.
Ref 533092Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01. Expert Opin Drug Deliv. 2015 Jul;12(7):1107-20.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.